respiratory syncytial virus
AstraZeneca scores accelerated approval in US and Europe for respiratory syncytial virus drug
February 5, 2019Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, EMA, FDA, MEDI8897, pharma, respiratory syncytial virus
It’s a double victory for AstraZeneca as the company announced its F monoclonal antibody MEDI8897 has been granted accelerated review …
Regeneron abandons respiratory syncytial virus therapy after late-stage failure
August 15, 2017Manufacturing and Production, Research and Development RSV, Regeneron, pharma, pharmaceuticals, respiratory syncytial virus
Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the …
UK biotech Pulmocide secures $30m for inhalable lung disease therapies
March 20, 2017Research and Development, Sales and Marketing pulmocide, pulmonary aspergillosis, respiratory syncytial virus
Pulmocide, a UK biotech run by a former GlaxoSmithKline scientists and based in London, has secured $30.4 million in Series …
AstraZeneca takes $445m hit to halt motavizumab
December 22, 2010Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus
AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
